Fresenius Medical Care AG (NYSE:FMS) Receives Average Recommendation of “Hold” from Analysts

Shares of Fresenius Medical Care AG (NYSE:FMS) have earned a consensus recommendation of “Hold” from the eight research firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $24.00.

Several research firms have recently weighed in on FMS. StockNews.com lowered shares of Fresenius Medical Care from a “strong-buy” rating to a “buy” rating in a research report on Friday, April 5th. Morgan Stanley cut shares of Fresenius Medical Care from an “equal weight” rating to an “underweight” rating in a report on Monday, January 8th.

Fresenius Medical Care Stock Performance

NYSE:FMS opened at $18.39 on Tuesday. Fresenius Medical Care has a twelve month low of $16.37 and a twelve month high of $27.72. The company has a current ratio of 1.42, a quick ratio of 1.07 and a debt-to-equity ratio of 0.47. The company has a 50-day moving average of $19.58 and a 200-day moving average of $19.54. The firm has a market cap of $10.79 billion, a price-to-earnings ratio of 19.99, a price-to-earnings-growth ratio of 0.91 and a beta of 1.00.

Fresenius Medical Care (NYSE:FMS) last posted its quarterly earnings data on Tuesday, February 20th. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.11. Fresenius Medical Care had a net margin of 2.56% and a return on equity of 4.99%. The company had revenue of $5.37 billion during the quarter, compared to analyst estimates of $5.32 billion. Analysts forecast that Fresenius Medical Care will post 1.53 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Comerica Bank acquired a new stake in shares of Fresenius Medical Care during the second quarter worth approximately $140,000. Bruce G. Allen Investments LLC acquired a new stake in shares of Fresenius Medical Care during the fourth quarter worth approximately $31,000. Hartford Financial Management Inc. boosted its holdings in shares of Fresenius Medical Care by 98.8% during the fourth quarter. Hartford Financial Management Inc. now owns 1,688 shares of the company’s stock worth $35,000 after purchasing an additional 839 shares during the period. Quilter Plc acquired a new stake in shares of Fresenius Medical Care during the first quarter worth approximately $1,824,421,000. Finally, Clear Street Markets LLC acquired a new stake in shares of Fresenius Medical Care during the fourth quarter worth approximately $28,000. 8.25% of the stock is currently owned by institutional investors and hedge funds.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.